USS Investment Management Ltd decreased its position in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 41.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,702 shares of the company’s stock after selling 99,522 shares during the period. USS Investment Management Ltd owned approximately 0.23% of Twist Bioscience worth $27,369,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in TWST. Westpac Banking Corp lifted its position in shares of Twist Bioscience by 156.7% in the third quarter. Westpac Banking Corp now owns 15,660 shares of the company’s stock worth $3,026,000 after buying an additional 9,560 shares in the last quarter. Private Advisor Group LLC bought a new position in Twist Bioscience during the third quarter valued at approximately $523,000. Ieq Capital LLC grew its holdings in Twist Bioscience by 7.5% during the 3rd quarter. Ieq Capital LLC now owns 54,948 shares of the company’s stock valued at $10,618,000 after buying an additional 3,839 shares in the last quarter. Stephens Investment Management Group LLC grew its holdings in Twist Bioscience by 1.7% during the 3rd quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock valued at $150,808,000 after buying an additional 13,055 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its stake in Twist Bioscience by 341.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 6,940 shares of the company’s stock worth $1,341,000 after acquiring an additional 5,369 shares during the last quarter.
Insider Buying and Selling
In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,797,004.32. Following the completion of the transaction, the insider directly owned 63,789 shares of the company’s stock, valued at $12,048,466.32. The trade was a 12.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the transaction, the senior vice president directly owned 106,632 shares of the company’s stock, valued at $20,140,652.16. The trade was a 8.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on TWST. Jefferies Financial Group set a $125.00 price objective on Twist Bioscience in a report on Thursday, November 12th. TD Cowen lowered their target price on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating for the company in a research report on Friday, November 13th. Royal Bank Of Canada set a $137.00 target price on shares of Twist Bioscience in a report on Friday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Finally, Barclays decreased their price target on shares of Twist Bioscience from $215.00 to $130.00 and set an “overweight” rating on the stock in a research note on Monday. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Hold” and an average target price of $133.92.
View Our Latest Analysis on Twist Bioscience
Twist Bioscience Trading Down 4.1%
Shares of NASDAQ TWST opened at $111.62 on Friday. The business’s 50 day moving average is $149.02 and its two-hundred day moving average is $94.44. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.86 and a quick ratio of 2.38. Twist Bioscience Corporation has a 1-year low of $25.67 and a 1-year high of $219.71. The stock has a market capitalization of $7.00 billion, a P/E ratio of -53.41 and a beta of 2.25.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative return on equity of 22.18% and a negative net margin of 28.34%. The firm’s revenue for the quarter was up 26.7% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience Corporation will post -1.42 EPS for the current year.
Twist Bioscience Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Recommended Stories
- Five stocks we like better than Twist Bioscience
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
